Another one for Boston Scientific to put down to experience
This article was originally published in Clinica
News last week that the US Food & Drug Administration had lifted the remaining restrictions on Boston Scientific's implantable cardiac defibrillators (ICD) and cardiac resynchronisation therapy (CRT) devices was welcomed at a company that has not had the rub of the green this year.
You may also be interested in...
The consensus among investors is that medtech has been the best-performing part of health care for the past three to four years, and investment levels remain good. Seemingly all-encompassing of late has been companies’ preoccupation with digital strategies, but there is a lot more to this unique industry than just digital.
With fewer than a hundred days left before the EU Medical Device Regulations kick in, Medtech Insight’s executive editor Ashley Yeo and managing editor Amanda Maxwell discuss in this week's podcast growing concerns by medtech industry members that they may not be ready in time to comply with the regulations and may inadvertently run afoul of them.
ABHI director of value and access Luella Trickett talks about the importance of real-world evidence in product development and value-based procurement in secondary care in the UK.